Fate Therapeutics Stock Performance
| FATE Stock | USD 3.17 0.49 18.28% |
The firm shows a Beta (market volatility) of 2.31, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Fate Therapeutics will likely underperform. Fate Therapeutics right now shows a risk of 5.81%. Please confirm Fate Therapeutics skewness, as well as the relationship between the rate of daily change and price action indicator , to decide if Fate Therapeutics will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Fate Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, Fate Therapeutics is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
Actual Historical Performance (%)
One Day Return 18.28 | Five Day Return 50.95 | Year To Date Return (14.09) | Ten Year Return (18.30) | All Time Return (52.11) |
1 | Bruce Co. Inc. Has 984,000 Position in Fate Therapeutics, Inc. | 09/16/2024 |
2 | Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635 | 10/02/2024 |
3 | Disposition of tradable shares by Jerome Bressi of Fate Therapeutics subject to Rule 16b-3 | 10/08/2024 |
4 | NVOs Rybelsus Meets Primary Goal in MACE Study for Diabetes Patients | 10/22/2024 |
5 | INCY Q3 Earnings Miss Estimates, Revenues Beat on Higher Product Sales | 10/29/2024 |
6 | Disposition of 11553 shares by Cindy Tahl of Fate Therapeutics at 5.24 subject to Rule 16b-3 | 10/30/2024 |
7 | Protagonist Therapeutics Reports Q3 Loss, Tops Revenue Estimates | 11/07/2024 |
8 | FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus | 11/13/2024 |
9 | Fate Therapeutics Third Quarter 2024 Earnings Beats Expectations | 11/14/2024 |
10 | Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated inPhase 1 Autoimmunity Study with Fludarabine-free Conditioning andFT819 Off-the-shel... | 11/18/2024 |
11 | Fate Therapeutics to Present at Upcoming December Investor Conferences | 11/26/2024 |
| Begin Period Cash Flow | 76.6 M |
Fate |
Fate Therapeutics Relative Risk vs. Return Landscape
If you would invest 345.00 in Fate Therapeutics on August 31, 2024 and sell it today you would lose (28.00) from holding Fate Therapeutics or give up 8.12% of portfolio value over 90 days. Fate Therapeutics is currently generating 0.0265% in daily expected returns and assumes 5.8071% risk (volatility on return distribution) over the 90 days horizon. In different words, 51% of stocks are less volatile than Fate, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Fate Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Fate Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Fate Therapeutics, and traders can use it to determine the average amount a Fate Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0046
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | FATE |
Estimated Market Risk
| 5.81 actual daily | 51 51% of assets are less volatile |
Expected Return
| 0.03 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Fate Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Fate Therapeutics by adding Fate Therapeutics to a well-diversified portfolio.
Fate Therapeutics Fundamentals Growth
Fate Stock prices reflect investors' perceptions of the future prospects and financial health of Fate Therapeutics, and Fate Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Fate Stock performance.
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.22 | ||||
| Operating Margin | (17.04) % | ||||
| Current Valuation | 163.1 M | ||||
| Shares Outstanding | 113.89 M | ||||
| Price To Earning | (4.35) X | ||||
| Price To Book | 1.00 X | ||||
| Price To Sales | 26.85 X | ||||
| Revenue | 63.53 M | ||||
| Gross Profit | (224.15 M) | ||||
| EBITDA | (172.23 M) | ||||
| Net Income | (160.93 M) | ||||
| Cash And Equivalents | 568.85 M | ||||
| Cash Per Share | 5.86 X | ||||
| Total Debt | 103.54 M | ||||
| Debt To Equity | 0.19 % | ||||
| Current Ratio | 6.55 X | ||||
| Book Value Per Share | 3.18 X | ||||
| Cash Flow From Operations | (132.26 M) | ||||
| Earnings Per Share | (1.64) X | ||||
| Market Capitalization | 361.04 M | ||||
| Total Asset | 506.22 M | ||||
| Retained Earnings | (1.21 B) | ||||
| Working Capital | 292.45 M | ||||
| Current Asset | 47.4 M | ||||
| Current Liabilities | 14.68 M | ||||
About Fate Therapeutics Performance
By analyzing Fate Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Fate Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Fate Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Fate Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.32) | (0.33) | |
| Return On Capital Employed | (0.41) | (0.43) | |
| Return On Assets | (0.32) | (0.33) | |
| Return On Equity | (0.44) | (0.46) |
Things to note about Fate Therapeutics performance evaluation
Checking the ongoing alerts about Fate Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Fate Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Fate Therapeutics had very high historical volatility over the last 90 days | |
| Fate Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 63.53 M. Net Loss for the year was (160.93 M) with loss before overhead, payroll, taxes, and interest of (224.15 M). | |
| Fate Therapeutics currently holds about 568.85 M in cash with (132.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.86, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Fate Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Fate Therapeutics to Present at Upcoming December Investor Conferences |
- Analyzing Fate Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Fate Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Fate Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Fate Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Fate Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Fate Therapeutics' stock. These opinions can provide insight into Fate Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Fate Stock analysis
When running Fate Therapeutics' price analysis, check to measure Fate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fate Therapeutics is operating at the current time. Most of Fate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fate Therapeutics' price. Additionally, you may evaluate how the addition of Fate Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |